Bacillus Calmette-Guérin (BCG) is an effective yet underutilized treatment for high-grade, nonemuscleinvasive bladder cancer. We evaluated the patterns of BCG utilization with respect to number of endoscopic resections in a Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database and found that BCG adoption is slow and incomplete. Methods to improve compliance with this therapy are warranted. Background: Bacillus Calmette-Guérin (BCG) is the reference standard treatment for patients with high-grade, none muscle-invasive bladder cancer (NMIBC). We previously described noncompliance with guidelines for BCG use in patients with high-risk disease. In the current study, we sought to characterize how the number of endoscopic resections of bladder tumors affects BCG utilization using population-level data. Patients and Methods: We queried a Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database to evaluate claims records of 4776 patients diagnosed with high-grade NMIBC between 1992 and 2002 and followed until 2007, who survived for at least 2 years and who did not undergo definitive treatment with cystectomy, radiotherapy, or systemic chemotherapy. We stratified patients on the basis of the number of endoscopic resections of bladder tumors. We used chi-square analysis to compare number of resections to BCG utilization and multinomial logistic regression analysis to quantify BCG utilization by patient and tumor characteristics. Results: Utilization of BCG increases with increasing endoscopic resections from 40% at diagnosis to 72% after 6 resections. The cumulative rate of at least an induction course of BCG plateaus after 3 resections. Lower BCG utilization was associated with advanced age ( 80 years), while increased utilization was associated with being married, higher disease stage (Tis and T1) and grade (undifferentiated), and increasing endoscopic resections. Conclusion: A significant fraction of patients with NMIBC do not receive induction BCG despite its proven benefit in minimizing recurrences. Most patients receive BCG only after multiple endoscopic resections. Strategies focused on earlier adoption of BCG to prevent recurrences instead of reacting to recurrences may limit progression and improve survival.
Introduction
High-grade urothelial cell carcinoma accounts for approximately 25% of newly diagnosed nonemuscle-invasive bladder cancer (NMIBC). 1 Within the first 2 years, approximately 61% will have at least 1 recurrence, and only 15% of these patients will proceed to aggressive treatment (ie, cystectomy, radiotherapy, or chemotherapy) after the first recurrence. 2, 3 Several studies have demonstrated that patients with high-grade NMIBC who opt for more aggressive treatment, for example cystectomy, do so early usually after the first recurrence. 3 Consequently, a significant fraction of patients with recurrent, high-grade NMIBC are managed primarily with endoscopic and intravesical treatments. Intravesical bacillus Calmette-Guérin (BCG) provided after transurethral resection of bladder tumor has been shown in multiple studies to reduce recurrence and progression in patients with highgrade NMIBC. 4, 5 Furthermore, maintenance BCG therapy has been shown to decrease recurrence in patients with NMIBC. 6 Unfortunately, adherence rates to standardized surveillance and treatment protocols for this disease are suboptimal. 7, 8 For example, less than half of patients in the landmark Southwest Oncology Group Trial 8507 completed 3 cycles of maintenance BCG, and only 16% of completed the full 7 cycles. 9 Despite data demonstrating increasing rates of BCG utilization, less than 30% of patients with high-grade NMIBC receive a full course of induction. 7 To our knowledge, utilization patterns of BCG on a population level as they relate to disease recurrence have not been described. The aim of our study was to further evaluate noncompliance with BCG by examining the association between number of endoscopic resections and BCG utilization. We speculated that up-front BCG therapy is underutilized and is instead utilized as a reaction to recurrence. Therefore, we hypothesized that the initiation of BCG would increase with the number of endoscopic resections, and that the number of patients completing maintenance therapy would be few.
Methods

Data Source
We used the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare database of the National Cancer Institute to acquire information on patients diagnosed with bladder cancer between 1992 and 2002 and followed until 2007. We restricted inclusion to those with Medicare fee-for-service coverage with complete data for Medicare Parts A and B for at least 12 months preceding bladder cancer diagnosis.
Study Population
Patients eligible for the study were 66 years or older to allow for at least 1 year of eligibility in Medicare before their diagnosis of bladder cancer to ascertain comorbidity data. As we have previously defined, eligible patients must have had an incident diagnosis of nonmetastatic (N0M0), high-grade (poorly or undifferentiated) urothelial cell (histology codes 8120, 8130), NMIBC (Ta, Tis, T1; International Classification of Diseases, Ninth Revision [ICD-9], 188.0-188.9, 233.7) diagnosed between January 1, 1992, and December 31, 2002. 2 We also limited our cohort to patients who survived at least 2 years without undergoing definitive treatment (cystectomy, radiation, systemic chemotherapy).
Induction BCG was defined as 6 weekly instillations. Maintenance was defined as 3 weekly instillations at 3, 6, 12, 18, and 24 months. On the basis of these recommended protocols, we classified BCG utilization into the following groups: no BCG (0 instillations during the entire followup period), partial induction (1-5 instillations), full induction (6 instillations), induction and 1 year of maintenance (7-15 instillations), induction and 2 years of maintenance (16-21 instillations) , and induction and > 2 years of maintenance ( 22 instillations).
Study Variables
We determined patient age, gender, race/ethnicity, marital status, tumor grade, and T stage using the Patient Entitlement and Diagnosis Summary File (PEDSF). Using 2000 US Census data, we determined levels of median house hold income and percent of residents 25 years or older with at least 4 years of college education. Similarly, using the Unique Physician Identifier Number, we were able to determine treatment center region and institution type.
Statistical Analysis
Bivariable analysis comparing utilization of BCG to the number of endoscopic resections (ie, transurethral resection of bladder tumor and biopsies of bladder) was performed by chi-square analysis. To quantify the association between utilization of BCG (partial, induction, or induction followed by maintenance) and our study variables, we used a multivariate, multinomial logistic regression analysis. We report the relative risk ratio (RRR) and the corresponding 95% confidence interval (CI).
The institutional review board at the University of California, Los Angeles, exempted our study from review. All analyses were conduced by Stata 13.1 software (StataCorp, College Station, TX). Statistical tests were all 2-tailed, with the probability of a type I error set at .05.
Results
Cohort characteristics for the 4776 patients meeting the inclusion criteria are listed in Table 1 BCG utilization was stratified by the number of resections ( Table 2) . Of the 1590 patients who underwent a single resection, 59.6% did not receive any BCG therapy, 25.8% received partial induction, 7.1% received full induction courses, and 7.5% received treatment beyond induction. The percentage of patients receiving at least partial BCG increased as the number of resections increased (chi-square analysis, P < .05). Figure 1 demonstrates cumulative BCG utilization. Cumulative use increased from 11% after the first resection to 20% after the third resection. An additional fourth and fifth resection only yielded a 2% increase in cumulative BCG utilization. After the fifth resection, we found no increase in BCG utilization.
In Table 3 , the RRR for partial BCG, induction BCG, and induction followed by maintenance BCG (compared to no BCG as a referent) is defined for several variables. We found that those of advanced age and female gender were less likely to receive BCG
e26 -Clinical Genitourinary Cancer February 2017
Endoscopic Resection and Bacillus Calmette-Guérin 
Discussion
High-grade NMIBC poses a treatment dilemma, given that recurrence is common and only a small fraction of patients undergo definitive therapy with cystectomy, radiation, or systemic chemotherapy. 3 Consequently, many patients with disease recurrence are treated with endoscopic and intravesical therapy. We sought to evaluate the relationship between the number of endoscopic resections and BCG use to understand how compliance and utilization may be optimized. Our study has 5 principal findings: (1) only 40% of patients received any BCG after a single resection; (2) over 60% of those who did receive BCG after the first resection had an incomplete induction course (< 6 instillations); (3) BCG use increases with multiple resections; (4) chronological age but not medical comorbidities were associated with less BCG use; and (5) patients diagnosed and treated at academic medical centers were no more likely to receive BCG therapy than those treated elsewhere. These observations demonstrate that there is substantial opportunity to improve the rate of BCG induction and maintenance, especially in the current era of limited access to BCG. There is widespread consensus that induction BCG is standard adjuvant treatment for high-risk NMIBC. 10 In a poll by Nielsen et al, 99% of urologists reported using induction therapy (including mitomycin C) after a diagnosis of high-grade disease, most commonly with BCG. 11 However, in our study, only 40% of patients received any BCG therapy after a single resection. This result is similar to data published previously. For example, Patschan et al analyzed a Swedish cohort of patients with T1 disease and found that only 24% received BCG. 12 Utilizing SEEReMedicare data, Spencer et al found that only 39% of patients with Tis or T1 disease and only 29% of patients with high-grade disease received any with low-grade yet high-risk disease (eg, multiple tumors, multiple recurrences), all patients in our cohort had high-grade disease and should have received BCG according to commonly used guidelines. Our second major finding was that the majority of BCG courses in our cohort is incomplete. By stratifying BCG use into number of instillations, we were able to analyze utilization more critically than many of the previously cited population-based studies. More than 60% of patients in our cohort who received BCG after the first resection received less than the standard induction. Although no data exist to suggest a shorter induction course, we do know that 6 instillations is sufficient to develop a delayed hypersensitivity reaction and has been shown to be efficacious in randomized trials. [16] [17] [18] Furthermore, the protective effects of BCG wane with time, and subjects require periodic maintenance instillations to induce durability. 19 Unfortunately, in our cohort, less than 1% of patients received induction therapy followed by more than 2 years of maintenance therapy. 21 Patients receiving these regimens may have artificially skewed our cohort to appear less compliant. We also demonstrated that BCG is being used despite multiple endoscopic resections. We found that use of BCG (induction alone or induction followed by maintenance) occurs in approximately 11% of our cohort after the first resection and takes 3 subsequent resections before cumulative use plateaus near 22%. While adjuvant BCG is known to limit recurrence and progression, there are also data to suggest that repeated BCG instillations in the face of persistent recurrences is associated with worse outcomes. Catalona et al demonstrated that each intravesical treatment increases the risk of metastasis, likely as a result of delayed definitive treatment. 22 Lambert et al also suggested that increasing intravesical therapy use is associated with poorer outcomes compared to those who underwent early cystectomy. 23 Identification of patients whose disease will fail to respond to BCG early is critical; Sogani and Herr have demonstrated that delaying radical cystectomy for high-risk NMIBC by longer than 2 years leads to worse disease-specific survival. 24 Ideally, all patients with high-grade NMIBC should be treated with early and should complete BCG therapy. Early BCG failure may then trigger a discussion regarding potential definitive therapy. It is known that older patients with more significant medical comorbidities do not respond to or tolerate BCG as well as younger, healthy patients. 25, 26 Our data support the observation that older 
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Clinical Genitourinary Cancer February 2017 -e29 patients ( 80 years) are less likely to receive BCG therapy. However, our analysis revealed that patients with greater comorbidities, as defined by the Charlson comorbidity scoring system, were no less likely to receive BCG. Thus, we have observed that age but not potential comorbidity status affects the decision to initiate BCG. In practice, we should consider that elderly patients with no medical comorbidities might respond to and benefit from intravesical BCG therapy. Finally, we expected to find that academic medical centers would be more likely to treat patients with BCG therapy. However, we were not able to confirm this hypothesis with our data. It is possible that patients referred to academic medical centers required secondline intravesical therapy as a result of BCG failure or intolerance. 27 Incorporation of these patients into our cohort would artificially skew our results to noncompliance. Another potential confounder is that patients treated at academic medical centers may have been more likely to be enrolled onto clinical trials that forego BCG therapy, although fewer of these trials existed at the time.
Our findings must be considered in the context of several limitations. First, this is a retrospective study that uses only Medicare patients aged > 66, and some patients diagnosed with bladder cancer are younger than the age captured by our data. Second, our choice of endoscopic resection as a marker of recurrence could not capture untreated recurrences, which may be substantial in this elderly population. Finally, we did not analyze alternative intravesical therapies or treatments being offered as second-line or salvage options.
Nevertheless, our data add to the current literature that demonstrates low levels of adherence to NMIBC treatment protocols by suggesting that the timing of BCG is often delayed and reactionary; current use is too little and too late to maximally affect recurrence and progression rates. Limiting recurrences may curb the substantial economic costs associated with chronic surveillance and multiple treatment cycles in NMIBC. 28 Finally, in light of the recent worldwide shortage of BCG, we must strive to optimize utilization of this limited resource. 29 Early and more complete utilization of BCG to limit recurrences, as opposed to reacting to them, may ultimately decrease progression and improve survival.
Conclusion
Despite significant evidence for use of BCG in an adjuvant setting to prevent recurrences, utilization of BCG in NMIBC has not yet been optimized. We show that despite multiple endoscopic resections, the cumulative adoption of BCG is incomplete, slow, and reactionary. To improve rates of progression and overall survival for patients with NMIBC, we should strive for earlier and more complete utilization of this proven therapy.
Clinical Practice Points
BCG is the standard reference treatment for high-grade NMIBC, yet compliance with this therapy is poor. We used a SEEReMedicare linked database to analyze BCG utilization with respect to number of endoscopic resections of bladder tumors. BCG utilization was low, even for patients who underwent multiple endoscopic resections of high-grade disease.
An increasing number of endoscopic resections were associated with increased utilization of BCG up to 3 resections, at which point utilization plateaued. BCG utilization is incomplete and reactionary; it should be used up front to prevent recurrences rather than react to them.
